Key Information for Ipsen S.A. Shareholders
Information regarding the Combined Shareholders’ Meeting of Ipsen S.A.
Formalities for Document Access
PARIS, FRANCE - Ipsen (Euronext: IPN) invites shareholders to its Combined Shareholders’ Meeting scheduled for Wednesday, 21 May at 3:00 p.m. (Paris time) in Paris. This significant meeting will provide essential updates and plans for the company’s future.
Documentation for the Meeting
The preliminary notice of the Meeting was publicly announced earlier in April and is available for scrutiny by shareholders. Comprehensive materials including the agenda, draft resolutions, and voting conditions can be found on Ipsen’s website under the Investors section. Shareholders interested in viewing these documents are encouraged to do so as they represent crucial insights into Ipsen S.A.'s operations.
Proposed Resolutions to be Approved
This meeting will specifically address several key resolutions:
- The proposed dividend of €1.40 per share for the 2024 financial year, with the ex-date set for 4 June and payment on 6 June.
- Renewal of the terms for four Directors: Mr. David LOEW, Mr. Antoine FLOCHEL, Mrs. Margaret LIU, and Mrs. Karen WITTS, maintaining balance in the Board's gender representation and independence.
Shareholder Participation Rights
In compliance with regulatory standards, registered shareholders can request the meeting documents until five days before the event. Bearer shareholders must provide a shareholding certificate prior to accessing these documents. Furthermore, all shareholders are invited to consult the documents directly at the company headquarters, ensuring transparency and open communication.
About Ipsen
Ipsen is a global biopharmaceutical leader dedicated to developing transformative therapies in oncology, rare diseases, and neuroscience. With nearly a century of expertise and operational hubs in the U.S., France, and the U.K., the company relies heavily on external collaboration to enhance its pipeline, bringing medication to patients across over 80 countries. This continued innovation positions Ipsen (Euronext: IPN) as a significant player in the pharmaceutical industry.
Company Contacts
Investors: Khalid DEOJEE | + 33 6 66 01 95 26 | khalid.deojee@ipsen.com
Media Contacts:
- Sally BAIN | + 1 857 320 0517 | sally.bain@ipsen.com
- Anne LIONTAS | + 33 7 67 34 72 96 | anne.liontas.ext@ipsen.com
Frequently Asked Questions
What is the date of the Ipsen S.A. Annual General Meeting?
The Combined Shareholders’ Meeting will take place on 21 May 2025 at 3:00 p.m. Paris time.
Where can shareholders find the meeting documents?
The documents are available on Ipsen's website under the Investors / Regulated Information / Shareholders Meeting section.
What resolutions will be proposed during the meeting?
Key resolutions include the approval of a €1.40 dividend per share and the renewal of terms for specific Directors on the Board.
How can shareholders participate in the meeting?
Registered shareholders can request meeting documents in advance, and all shareholders can attend the meeting at the specified location.
What therapeutic areas does Ipsen focus on?
Ipsen primarily focuses on oncology, rare diseases, and neuroscience, striving to deliver transformative treatments to patients globally.
